Filgrastim biosimilar - Hospira

Drug Profile

Filgrastim biosimilar - Hospira

Alternative Names: FILGRASTIM-AAFI; Nivestim; Nivestym

Latest Information Update: 26 Jul 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Hospira
  • Class Chemoprotectants; Granulocyte colony-stimulating factors; Neuroprotectants
  • Mechanism of Action Granulocyte colony stimulating factor stimulants; Haematopoiesis stimulants; Haematopoietic cell growth factor stimulants; Nerve growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Febrile neutropenia; Neutropenia

Most Recent Events

  • 20 Jul 2018 Registered for Neutropenia (Chemotherapy-induced) in USA (IV)
  • 20 Jul 2018 Registered for Neutropenia (Chemotherapy-induced) in USA (SC)
  • 01 Jan 2017 Pfizer completes a phase I trial in Healthy volunteers in USA (SC) (NCT02923791)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top